Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib for bipolar disorder
IRCT20221216056832N1Phase 3Completed
- Sponsor
- Babol University of Medical Sciences
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of celecoxib in bipolar disorder (BD) (2 arms), sponsored by Babol University of Medical Sciences. Primary endpoint: Treatment of signs and symptoms in patients diagnosed with bipolar disorder. Started Dec 2022; status: completed.
02
Drugs
celecoxib
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on IRCT20221216056832N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221216056832N1.